公开(公告)号：US12049530B2

公开(公告)日：2024-07-30

申请号：US17150796

申请日：2021-01-15

申请人： The Johns Hopkins University

发明人： Jordan J. Green ,  Joel C. Sunshine ,  Nupura S. Bhise ,  Ron B. Shmueli ,  Stephany Y. Tzeng

IPC分类号： C08F222/10 ,  A61K9/107 ,  A61K31/713 ,  A61K38/02 ,  A61K47/20 ,  A61K48/00 ,  C07C229/12 ,  C07C323/25 ,  C08G73/02 ,  C12N15/88

CPC分类号： C08F222/102 ,  A61K9/1075 ,  A61K31/713 ,  A61K38/02 ,  A61K47/20 ,  C07C229/12 ,  C07C323/25 ,  C08G73/028 ,  C12N15/88 ,  A61K48/00

摘要： Degradable polymers were synthesized that self-assemble with DNA to form particles that are effective for gene delivery. Small changes to polymer synthesis conditions, particle formulation conditions, and polymer structure provides significant changes to efficacy in a cell-type dependent manner. Polymers presented here are more effective than commercially available materials, such as LIPOFECTAMINE 2000™, FUGENE®, or polyethylenimine (PEI), for gene delivery to cancerous fibroblasts or human primary fibroblasts. The presently disclosed materials may be useful for cancer therapeutics and regenerative medicine.

公开(公告)号：US11944640B2

公开(公告)日：2024-04-02

申请号：US16346286

申请日：2017-10-31

申请人： XYLONIX PTE. LTD.

发明人： Jinhyuk Fred Chung

IPC分类号： A61K9/70 ,  A24D1/02 ,  A61K33/30 ,  A61K33/44 ,  A61K38/02 ,  A61K47/54 ,  A61K47/55 ,  A61K47/62 ,  A61K47/64 ,  A61M15/06 ,  A61P35/00 ,  C01B32/156 ,  D21H27/00 ,  A61K31/20 ,  A61K33/243 ,  D21H19/38

CPC分类号： A61K33/30 ,  A61K38/02 ,  A61K47/542 ,  A61K47/551 ,  A61K47/62 ,  A61K47/645 ,  A61P35/00

摘要： The invention relates to pharmaceutical compositions comprising a zinc2+ salt and a γ-polyglutamic acid carrier, and, optionally, an NF-kB inhibitor as a tumor-sensitizing agent, and methods for using such compositions to treat tumors in patients. Methods include administering a liquid dosage form or a solid dosage form of a therapeutically effective amount of a Zn(II) salt and a γ-polyglutamic acid carrier to a patient in need thereof. Methods of treating a broad spectrum of human tumors, including tumors with a drug-resistant phenotype, using the disclosed compositions are provided. Tumors that respond to the pharmaceutical compositions disclosed herein include neuroendocrine (neuroblastoma), gastric, uterine, and lung tumors.

公开(公告)号：US20240076643A1

公开(公告)日：2024-03-07

申请号：US18471899

申请日：2023-09-21

申请人： Jazz Pharmaceuticals Ireland Ltd.

发明人： Lars Friedrich ,  Anne O'Donnell

IPC分类号： C12N9/82

CPC分类号： C12N9/82 ,  C12Y305/01001 ,  A61K38/02

摘要： The disclosure provides a modified protein that is a combination of (i) an L-asparaginase and (ii) one or more (poly)peptide(s), wherein the (poly)peptide consists solely of proline and alanine amino acid residues, and methods of preparation and use thereof.

公开(公告)号：US20240041812A1

公开(公告)日：2024-02-08

申请号：US18235533

申请日：2023-08-18

申请人： SOCIÉTÉ DES PRODUITS NESTLÉ S.A. ,  BAYLOR COLLEGE OF MEDICINE

发明人： Stephen Kirnon ,  Eric Freedland ,  Rajagopal V. Sekhar

IPC分类号： A61K31/198 ,  A61K38/05 ,  A61K31/167 ,  A61K31/223 ,  A61K31/341 ,  A61K38/21 ,  A61K31/683 ,  A61K31/27 ,  A61K45/06 ,  A61K31/381 ,  A61K31/205 ,  A61P39/06 ,  A23K20/142 ,  A23K50/50 ,  A61P21/00 ,  A61P39/00 ,  A61P31/18 ,  A61P29/00 ,  A61K38/02

CPC分类号： A61K31/198 ,  A61K38/05 ,  A61K31/167 ,  A61K31/223 ,  A61K31/341 ,  A61K38/21 ,  A61K31/683 ,  A61K31/27 ,  A61K45/06 ,  A61K31/381 ,  A61K31/205 ,  A61P39/06 ,  A23K20/142 ,  A23K50/50 ,  A61P21/00 ,  A61P39/00 ,  A61P31/18 ,  A61P29/00 ,  A61K38/02

摘要： Compositions and methods are related to utilizing glycine and N-acetylcysteine for a variety of medical conditions related to reduced levels of glycine, N-acetylcysteine, and/or glutathione, for example, muscle loss such as sarcopenia, HIV infection and other infections, organ damage such as those from diabetes and insulin resistance and diabetic nephropathy, cardiac function and failure such as preventing or improving heart failure, fatty liver, cancer prevention, and other conditions.

公开(公告)号：US11884727B2

公开(公告)日：2024-01-30

申请号：US17186960

申请日：2021-02-26

申请人： Yeda Research and Development Co. Ltd.

发明人： Michal Eisenbach-Schwartz ,  Kuti Baruch ,  Neta Rosenzweig

IPC分类号： C07K16/28 ,  A61K39/395 ,  A61P25/28 ,  A61P37/02 ,  A61K38/00 ,  A61K38/14 ,  A61K45/06 ,  A61K31/404 ,  A61K31/7068 ,  A61K33/36 ,  A61K38/16 ,  A61K38/18 ,  A61K38/20 ,  A61K31/4155 ,  A61K38/02 ,  A61K39/00

CPC分类号： C07K16/2803 ,  A61K31/404 ,  A61K31/4155 ,  A61K31/7068 ,  A61K33/36 ,  A61K38/00 ,  A61K38/005 ,  A61K38/02 ,  A61K38/14 ,  A61K38/168 ,  A61K38/18 ,  A61K38/208 ,  A61K39/395 ,  A61K39/3955 ,  A61K39/39541 ,  A61K45/06 ,  C07K16/2818 ,  C07K16/2827 ,  A61K2039/505 ,  A61K2039/507 ,  A61K2039/545 ,  A61K2039/57 ,  A61K2039/572 ,  A61K2121/00 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/75 ,  C07K2317/76 ,  A61K38/208 ,  A61K2300/00 ,  A61K33/36 ,  A61K2300/00 ,  A61K31/404 ,  A61K2300/00 ,  A61K31/4155 ,  A61K2300/00 ,  A61K31/7068 ,  A61K2300/00

摘要： A pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of the CNS that does not include the autoimmune neuroinflammatory disease, relapsing-remitting multiple sclerosis (RRMS), is provided. The pharmaceutical composition is for administration by a dosage regimen comprising at least two courses of therapy, each course of therapy comprising in sequence a treatment session followed by an interval session.

公开(公告)号：US11730711B2

公开(公告)日：2023-08-22

申请号：US17175111

申请日：2021-02-12

申请人： SOCIÉTÉ DES PRODUITS NESTLÉ S.A. ,  BAYLOR COLLEGE OF MEDICINE

发明人： Stephen Kirnon ,  Eric Freedland ,  Rajagopal V. Sekhar

IPC分类号： A61K31/198 ,  A61K38/05 ,  A61K31/167 ,  A61K31/223 ,  A61K31/341 ,  A61K38/21 ,  A61K31/683 ,  A61K31/27 ,  A61K45/06 ,  A61K31/381 ,  A61K31/205 ,  A23K20/142 ,  A23K50/50 ,  A61P21/00 ,  A61P39/00 ,  A61P31/18 ,  A61P29/00 ,  A61K38/02

CPC分类号： A61K31/198 ,  A23K20/142 ,  A23K50/50 ,  A61K31/167 ,  A61K31/205 ,  A61K31/223 ,  A61K31/27 ,  A61K31/341 ,  A61K31/381 ,  A61K31/683 ,  A61K38/02 ,  A61K38/05 ,  A61K38/21 ,  A61K45/06 ,  A61P21/00 ,  A61P29/00 ,  A61P31/18 ,  A61P39/00 ,  A61K31/198 ,  A61K2300/00 ,  A61K31/167 ,  A61K2300/00 ,  A61K31/27 ,  A61K2300/00 ,  A61K31/205 ,  A61K2300/00 ,  A61K31/223 ,  A61K2300/00 ,  A61K31/381 ,  A61K2300/00 ,  A61K31/341 ,  A61K2300/00 ,  A61K31/683 ,  A61K2300/00 ,  A61K38/21 ,  A61K2300/00

摘要： Compositions and methods are related to utilizing glycine and N-acetylcysteine for a variety of medical conditions related to reduced levels of glycine, N-acetylcysteine, and/or glutathione, for example, muscle loss such as sarcopenia, HIV infection and other infections, organ damage such as those from diabetes and insulin resistance and diabetic nephropathy, cardiac function and failure such as preventing or improving heart failure, fatty liver, cancer prevention, and other conditions.

公开(公告)号：US11712423B2

公开(公告)日：2023-08-01

申请号：US17222089

申请日：2021-04-05

申请人： Nicholas L. Abbott ,  Christopher J. Murphy

发明人： Nicholas L. Abbott ,  Christopher J. Murphy

IPC分类号： A61K38/17 ,  A61K47/42 ,  A61K9/70 ,  A61K48/00 ,  A61K9/00 ,  A61K45/06 ,  A61K31/00 ,  A61K31/095 ,  A61K31/375 ,  A61K31/66 ,  A61K31/70 ,  A61K31/7088 ,  A61K31/726 ,  A61K38/02 ,  A61K38/05

CPC分类号： A61K9/70 ,  A61K9/006 ,  A61K9/0014 ,  A61K9/0034 ,  A61K9/0043 ,  A61K9/0048 ,  A61K31/00 ,  A61K31/095 ,  A61K31/375 ,  A61K31/66 ,  A61K31/70 ,  A61K31/7088 ,  A61K31/726 ,  A61K38/02 ,  A61K38/05 ,  A61K38/1735 ,  A61K45/06 ,  A61K47/42 ,  A61K48/0075

摘要： The present invention relates to methods and compositions for modifying mucous membranes. In particular, the present invention relates to treating diseases associated with mucous membranes by changing the intrinsic chemical composition and/or physical features of a target mucous membrane.

公开(公告)号：US11667784B2

公开(公告)日：2023-06-06

申请号：US16043992

申请日：2018-07-24

申请人： REGENTS OF THE UNIVERSITY OF MINNESOTA

发明人： Theresa Reineke ,  Craig Van Bruggen

IPC分类号： C08L39/00 ,  A61K47/50 ,  A61K47/58 ,  A61K31/49 ,  A61K48/00 ,  C08F220/56 ,  C08L33/14 ,  C08L33/24 ,  A61K47/32 ,  A61K38/02 ,  C12N15/87

CPC分类号： C08L39/00 ,  A61K31/49 ,  A61K47/32 ,  A61K47/50 ,  A61K47/58 ,  A61K48/0041 ,  C08F220/56 ,  C08L33/14 ,  C08L33/24 ,  A61K38/02 ,  C08L2203/02 ,  C12N15/87 ,  C08F220/56 ,  C08F226/02

摘要： Copolymers polymerized from at least one or more cinchona alkaloid containing compounds; and an acrylamide containing monomer, an acrylate containing monomer, or combinations thereof. Method of forming a copolymer-genetic component complex that includes a genetic component and a copolymer where the copolymer includes one or more cinchona alkaloid containing compounds and an acrylamide containing monomer, an acrylate containing monomer, or combinations thereof. Methods of delivering a genetic component to a cell.

公开(公告)号：US20230146324A1

公开(公告)日：2023-05-11

申请号：US17683235

申请日：2022-02-28

申请人： ModernaTX, Inc.

发明人： John van Wicheren REYNDERS, III ,  Tirtha CHAKRABORTY ,  Stephen HOGE ,  Iain James MCFADYEN

IPC分类号： C12P21/02 ,  A61K31/7088 ,  A61K38/02

CPC分类号： C12P21/02 ,  A61K31/7088 ,  A61K38/02 ,  C07K14/00

摘要： The present disclosure provides multiparametric codon optimization methods to improve at least a property in a candidate nucleic acid sequence, for example the translation efficacy of a therapeutic mRNA.

公开(公告)号：US20190247457A1

公开(公告)日：2019-08-15

申请号：US16309957

申请日：2017-06-16

申请人： The University of Tokyo ,  Osaka University

发明人： Hiroaki Suga ,  Nasir Kato Bashiruddin ,  Junichi Takagi ,  Yukiko Matsunaga

IPC分类号： A61K38/02 ,  A61P25/28 ,  A61P19/00 ,  A61K9/00

CPC分类号： A61K38/02 ,  A61K9/0019 ,  A61K9/0053 ,  A61K38/04 ,  A61P19/00 ,  A61P19/08 ,  A61P25/28 ,  A61P35/00 ,  A61P43/00 ,  C07K7/50

摘要： The present invention provides a Plexin-binding regulating agent containing a cyclic peptide having an Arg-Trp-Thr structure or a Leu-Ser-Trp structure or a pharmaceutically acceptable salt of the cyclic peptide.